Phase III GRAALL-R 2005 Study of Rituximab in CD20-Positive, Ph-Negative, B-Cell Precursor ALL


Phase III GRAALL-R 2005 Study of Rituximab in CD20-Positive, Ph-Negative, B-Cell Precursor ALL
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Maury S et al. Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): Results of the randomized Graall-R 2005 study. Proc ASH 2015;Abstract 1.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.